From proteins to genes: Immunoanalysis in the diagnosis of muscular dystrophies

Skeletal Muscle

Volumn 1, Issue 1, 2011, Pages

  Barresi, Rita ^a,b  

^a NEWCASTLE DENTAL HOSPITAL   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84858602416     PISSN: None     EISSN: 20445040     Source Type: Journal    
DOI: 10.1186/2044-5040-1-24     Document Type: Review

References (136)

1. Gasper MC, Gilchrist JM. Creatine kinase: a review of its use in the diagnosis of muscle disease. Med Health R I 2005, 88:398. 400-394..
2. M Mercuri E, Bushby K, Ricci E, Birchall D, Pane M, Kinali M, Allsop J, Nigro V, Sáenz A, Nascimbeni A, Fulizio L, Angelini C, Muntoni F. Muscle MRI findings in patients with limb girdle muscular dystrophy with calpain 3 deficiency (LGMD2A) and early contractures. Neuromuscul Disord 2005, 15:164-171. 10.1016/j.nmd.2004.10.008, 15694138.
3. Fischer D, Walter MC, Kesper K, Petersen JA, Aurino S, Nigro V, Kubisch C, Meindl T, Lochmüller H, Wilhelm K, Urbach H, Schröder R. Diagnostic value of muscle MRI in differentiating LGMD2I from other LGMDs. J Neurol 2005, 252:538-547. 10.1007/s00415-005-0684-4, 15726252.
4. Mercuri E, Pichiecchio A, Allsop J, Messina S, Pane M, Muntoni F. Muscle MRI in inherited neuromuscular disorders: past, present, and future. J Magn Reson Imaging 2007, 25:433-440.
5. Sewry CA. Muscular dystrophies: an update on pathology and diagnosis. Acta Neuropathol 2010, 120:343-358. 10.1007/s00401-010-0727-5, 20652576.
6. Bornemann A, Anderson LV. Diagnostic protein expression in human muscle biopsies. Brain Pathol 2000, 10:193-214.
7. Anderson LV, Davison K. Multiplex western blotting system for the analysis of muscular dystrophy proteins. Am J Pathol 1999, 154:1017-1022. 10.1016/S0002-9440(10)65354-0, 1866550, 10233840.
8. Heckmatt JZ, Leeman S, Dubowitz V. Ultrasound imaging in the diagnosis of muscle disease. J Pediatr 1982, 101:656-660. 10.1016/S0022-3476(82)80286-2, 7131136.
9. Patton BL, Connoll AM, Martin PT, Cunningham JM, Mehta S, Pestronk A, Miner JH, Sanes JR. Distribution of ten laminin chains in dystrophic and regenerating muscles. Neuromuscul Disord 1999, 9:423-433. 10.1016/S0960-8966(99)00033-4, 10545049.
10. Sewry C, Dubowitz V. Immunohistochemistry. Muscle Biopsy: a Practical Approach 2007, 195-245. St. Louis, MO: Saunders Elsevier, 3.
11. Klinge L, Harris J, Sewry C, Charlton R, Anderson L, Laval S, Chiu YH, Hornsey M, Straub V, Barresi R, Lochmüller H, Bushby K. Dysferlin associates with the developing T-tubule system in rodent and human skeletal muscle. Muscle Nerve 2010, 41:166-173. 10.1002/mus.21166, 20082313.
12. Barresi R, Campbell KP. Dystroglycan: from biosynthesis to pathogenesis of human disease. J Cell Sci 2006, 119:199-207. 10.1242/jcs.02814, 16410545.
13. Lim LE, Campbell KP. The sarcoglycan complex in limb-girdle muscular dystrophy. Curr Opin Neurol 1998, 11:443-452.
14. Ozawa E, Noguchi S, Mizuno Y, Hagiwara Y, Yoshida M. From dystrophinopathy to sarcoglycanopathy: evolution of a concept of muscular dystrophy. Muscle Nerve 1998, 21:421-438. 10.1002/(SICI)1097-4598(199804)21:4<421::AID-MUS1>3.0.CO;2-B, 9533777.
15. Straub V, Campbell KP. Muscular dystrophies and the dystrophin-glycoprotein complex. Curr Opin Neurol 1997, 10:168-175. 10.1097/00019052-199704000-00016, 9146999.
16. Jung D, Yang B, Meyer J, Chamberlain JS, Campbell KP. Identification and characterization of the dystrophin anchoring site on beta-dystroglycan. J Biol Chem 1995, 270:27305-27310. 10.1074/jbc.270.45.27305, 7592992.
17. Suzuki A, Yoshida M, Yamamoto H, Ozawa E. Glycoprotein-binding site of dystrophin is confined to the cysteine-rich domain and the first half of the carboxy-terminal domain. FEBS Lett 1992, 308:154-160. 10.1016/0014-5793(92)81265-N, 1499724.
18. Sadoulet-Puccio HM, Rajala M, Kunkel LM. Dystrobrevin and dystrophin: an interaction through coiled-coil motifs. Proc Natl Acad Sci USA 1997, 94:12413-12418. 10.1073/pnas.94.23.12413, 24974, 9356463.
19. Suzuki A, Yoshida M, Ozawa E. Mammalian α1- and β1-syntrophin bind to the alternative splice-prone region of the dystrophin COOH terminus. J Cell Biol 1995, 128:373-381. 10.1083/jcb.128.3.373, 2120347, 7844151.
20. Crosbie RH, Heighway J, Venzke DP, Lee JC, Campbell KP. Sarcospan, the 25-kDa transmembrane component of the dystrophin-glycoprotein complex. J Biol Chem 1997, 272:31221-31224. 10.1074/jbc.272.50.31221, 9395445.
21. Beedle AM, Nienaber PM, Campbell KP. Fukutin-related protein associates with the sarcolemmal dystrophin-glycoprotein complex. J Biol Chem 2007,
22. Ervasti JM, Campbell KP. Membrane organization of the dystrophin-glycoprotein complex. Cell 1991, 66:1121-1131. 10.1016/0092-8674(91)90035-W, 1913804.
23. Arahata K, Ishihara T, Kamakura K, Tsukahara T, Ishiura S, Baba C, Matsumoto T, Nonaka I, Sugita H. Mosaic expression of dystrophin in symptomatic carriers of Duchenne's muscular dystrophy. New Engl J Med 1989, 320(3):138-142. 10.1056/NEJM198901193200302, 2643040.
24. Tuffery-Giraud S, Saquet C, Chambert S, Echenne B, Marie Cuisset J, Rivier F, Cossée M, Philippe C, Monnier N, Bieth E, Recan D, Antoinette Voelckel M, Perelman S, Lambert JC, Malcolm S, Claustres M. The role of muscle biopsy in analysis of the dystrophin gene in Duchenne muscular dystrophy: experience of a national referral centre. Neuromuscul Disord 2004, 14:650-658. 10.1016/j.nmd.2004.05.002, 15351422.
25. Deburgrave N, Daoud F, Llense S, Barbot JC, Récan D, Peccate C, Burghes AH, Béroud C, Garcia L, Kaplan JC, Chelly J, Leturcq F. Protein- and mRNA-based phenotype-genotype correlations in DMD/BMD with point mutations and molecular basis for BMD with nonsense and frameshift mutations in the DMD gene. Hum Mutat 2007, 28:183-195. 10.1002/humu.20422, 17041906.
26. Muntoni F, Torelli S, Ferlini A. Dystrophin and mutations: one gene, several proteins, multiple phenotypes. Lancet Neurol 2003, 2:731-740. 10.1016/S1474-4422(03)00585-4, 14636778.
27. Nicholson LV, Johnson MA, Bushby KM, Gardner-Medwin D, Curtis A, Ginjaar IB, den Dunnen JT, Welch JL, Butler TJ, Bakker E. Integrated study of 100 patients with Xp21 linked muscular dystrophy using clinical, genetic, immunochemical, and histopathological data. Part 3. Differential diagnosis and prognosis. J Med Genet 1993, 30:745-751. 10.1136/jmg.30.9.745, 1016531, 8411069.
28. Thanh LT, Man NT, Hori S, Sewry CA, Dubowitz V, Morris GE. Characterization of genetic deletions in Becker muscular dystrophy using monoclonal antibodies against a deletion-prone region of dystrophin. Am J Med Genet 1995, 58:177-186. 10.1002/ajmg.1320580217, 8533812.
29. Clerk A, Rodillo E, Heckmatt JZ, Dubowitz V, Strong PN, Sewry CA. Characterisation of dystrophin in carriers of Duchenne muscular dystrophy. J Neurol Sci 1991, 102:197-205. 10.1016/0022-510X(91)90069-J, 2072119.
30. Sewry CA, Matsumura K, Campbell KP, Dubowitz V. Expression of dystrophin-associated glycoproteins and utrophin in carriers of Duchenne muscular dystrophy. Neuromuscul Disord 1994, 4:401-409. 10.1016/0960-8966(94)90079-5, 7881285.
31. Clerk A, Rodillo E, Heckmatt JZ, Dubowitz V, Strong PN, Sewry CA. Characterisation of dystrophin in carriers of Duchenne muscular dystrophy. J Neurol Sci 1991, 102:197-205. 10.1016/0022-510X(91)90069-J, 2072119.
32. Mizuno Y, Nonaka I, Hirai S, Ozawa E. Reciprocal expression of dystrophin and utrophin in muscles of Duchenne muscular dystrophy patients, female DMD-carriers and control subjects. J Neurol Sci 1993, 119:43-52. 10.1016/0022-510X(93)90190-A, 8246010.
33. Sewry CA, Nowak KJ, Ehmsen JT, Davies KE. A and B utrophin in human muscle and sarcolemmal A-utrophin associated with tumours. Neuromuscul Disord 2005, 15:779-785. 10.1016/j.nmd.2005.08.002, 16198105.
34. Taylor J, Muntoni F, Dubowitz V, Sewry CA. The abnormal expression of utrophin in Duchenne and Becker muscular dystrophy is age related. Neuropathol Appl Neurobiol 1997, 23:399-405. 10.1111/j.1365-2990.1997.tb01314.x, 9364465.
35. Sewry CA, Sansome A, Matsumura K, Campbell KP, Dubowitz V. Deficiency of the 50 kDa dystrophin-associated glycoprotein and abnormal expression of utrophin in two south Asian cousins with variable expression of severe childhood autosomal recessive muscular dystrophy. Neuromuscul Disord 1994, 4:121-129. 10.1016/0960-8966(94)90003-5, 8012192.
36. Torelli S, Brown SC, Jimenez-Mallebrera C, Feng L, Muntoni F, Sewry CA. Absence of neuronal nitric oxide synthase (nNOS) as a pathological marker for the diagnosis of Becker muscular dystrophy with rod domain deletions. Neuropathol Appl Neurobiol 2004, 30:540-545. 10.1111/j.1365-2990.2004.00561.x, 15488030.
37. Tews DS, Goebel HH, Schneider I, Gunkel A, Stennert E, Neiss WF. Expression of different isoforms of nitric oxide synthase in experimentally denervated and reinnervated skeletal muscle. J Neuropathol Exp Neurol 1997, 56:1283-1289. 10.1097/00005072-199712000-00003, 9413277.
38. Sewry CA, Taylor J, Anderson LV, Ozawa E, Pogue R, Piccolo F, Bushby K, Dubowitz V, Muntoni F. Abnormalities in alpha-, beta- and gamma-sarcoglycan in patients with limb-girdle muscular dystrophy. Neuromuscul Disord 1996, 6:467-474. 10.1016/S0960-8966(96)00389-6, 9027857.
39. Anderson LV. Optimized protein diagnosis in the autosomal recessive limb-girdle muscular dystrophies. Neuromuscul Disord 1996, 6:443-446. 10.1016/S0960-8966(96)00385-9, 9027853.
40. Bonnemann CG, Wong J, Jones KJ, Lidov HG, Feener CA, Shapiro F, Darras BT, Kunkel LM, North KN. Primary gamma-sarcoglycanopathy (LGMD 2C): broadening of the mutational spectrum guided by the immunohistochemical profile. Neuromuscul Disord 2002, 12:273-280. 10.1016/S0960-8966(01)00276-0, 11801399.
41. Vainzof M, Passos-Bueno MR, Canovas M, Moreira ES, Pavanello RC, Marie SK, Anderson LV, Bonnemann CG, McNally EM, Nigro V, Kunkel LM, Zatz M. The sarcoglycan complex in the six autosomal recessive limb-girdle muscular dystrophies. Hum Mol Genet 1996, 5:1963-1969. 10.1093/hmg/5.12.1963, 8968750.
42. Klinge L, Dekomien G, Aboumousa A, Charlton R, Epplen JT, Barresi R, Bushby K, Straub V. Sarcoglycanopathies: can muscle immunoanalysis predict the genotype?. Neuromuscul Disord 2008, 18:934-941. 10.1016/j.nmd.2008.08.003, 18996010.
43. Jones KJ, Kim SS, North KN. Abnormalities of dystrophin, the sarcoglycans, and laminin alpha2 in the muscular dystrophies. J Med Genet 1998, 35:379-386. 10.1136/jmg.35.5.379, 1051311, 9610800.
44. Pogue R, Anderson LV, Pyle A, Sewry C, Pollitt C, Johnson MA, Davison K, Moss JA, Mercuri E, Muntoni F, Bushby KM. Strategy for mutation analysis in the autosomal recessive limb-girdle muscular dystrophies. Neuromuscul Disord 2001, 11:80-87. 10.1016/S0960-8966(00)00154-1, 11166169.
45. Sewry CA. Immunocytochemical analysis of human muscular dystrophy. Microsc Res Tech 2000, 48:142-154. 10.1002/(SICI)1097-0029(20000201/15)48:3/4<142::AID-JEMT3>3.0.CO;2-9, 10679962.
46. Crosbie RH, Barresi R, Campbell KP. Loss of sarcolemma nNOS in sarcoglycan-deficient muscle. FASEB J 2002, 16:1786-1791. 10.1096/fj.02-0519com, 12409321.
47. Kobayashi YM, Rader EP, Crawford RW, Iyengar NK, Thedens DR, Faulkner JA, Parikh SV, Weiss RM, Chamberlain JS, Moore SA, Campbell KP. Sarcolemma-localized nNOS is required to maintain activity after mild exercise. Nature 2008, 456:511-515. 10.1038/nature07414, 2588643, 18953332.
48. Ibraghimov-Beskrovnaya O, Milatovich A, Ozcelik T, Yang B, Koepnick K, Francke U, Campbell KP. Human dystroglycan: skeletal muscle cDNA, genomic structure, origin of tissue specific isoforms and chromosomal localization. Hum Mol Genet 1993, 2:1651-1657. 10.1093/hmg/2.10.1651, 8268918.
49. Holt KH, Crosbie RH, Venzke DP, Campbell KP. Biosynthesis of dystroglycan: processing of a precursor propeptide. FEBS Lett 2000, 468:79-83. 10.1016/S0014-5793(00)01195-9, 10683445.
50. Hara Y, Balci-Hayta B, Yoshida-Moriguchi T, Kanagawa M, Beltrán-Valero de Bernabé D, Gündeşli H, Willer T, Satz JS, Crawford RW, Burden SJ, Kunz S, Oldstone MB, Accardi A, Talim B, Muntoni F, Topaloǧlu H, Dinçer P, Campbell KP. A dystroglycan mutation associated with limb-girdle muscular dystrophy. N Engl J Med 2011, 364:939-946. 10.1056/NEJMoa1006939, 21388311.
51. Brockington M, Blake DJ, Prandini P, Brown SC, Torelli S, Benson MA, Ponting CP, Estournet B, Romero NB, Mercuri E, Voit T, Sewry CA, Guicheney P, Muntoni F. Mutations in the fukutin-related protein gene (FKRP) cause a form of congenital muscular dystrophy with secondary laminin alpha2 deficiency and abnormal glycosylation of alpha-dystroglycan. Am J Hum Genet 2001, 69:1198-1209. 10.1086/324412, 1235559, 11592034.
52. Brockington M, Yuva Y, Prandini P, Brown SC, Torelli S, Benson MA, Herrmann R, Anderson LV, Bashir R, Burgunder JM, Fallet S, Romero N, Fardeau M, Straub V, Storey G, Pollitt C, Richard I, Sewry CA, Bushby K, Voit T, Blake DJ, Muntoni F. Mutations in the fukutin-related protein gene (FKRP) identify limb girdle muscular dystrophy 2I as a milder allelic variant of congenital muscular dystrophy MDC1C. Hum Mol Genet 2001, 10:2851-2859. 10.1093/hmg/10.25.2851, 11741828.
53. Godfrey C, Clement E, Mein R, Brockington M, Smith J, Talim B, Straub V, Robb S, Quinlivan R, Feng L, Jimenez-Mallebrera C, Mercuri E, Manzur AY, Kinali M, Torelli S, Brown SC, Sewry CA, Bushby K, Topaloglu H, North K, Abbs S, Muntoni F. Refining genotype phenotype correlations in muscular dystrophies with defective glycosylation of dystroglycan. Brain 2007, 130:2725-2735. 10.1093/brain/awm212, 17878207.
54. Muntoni F, Torelli S, Brockington M. Muscular dystrophies due to glycosylation defects. Neurotherapeutics 2008, 5:627-632. 10.1016/j.nurt.2008.08.005, 19019316.
55. Hewitt JE. Abnormal glycosylation of dystroglycan in human genetic disease. Biochim Biophys Acta 2009, 1792:853-861.
56. Michele DE, Barresi R, Kanagawa M, Saito F, Cohn RD, Satz JS, Dollar J, Nishino I, Kelley RI, Somer H, Straub V, Mathews KD, Moore SA, Campbell KP. Post-translational disruption of dystroglycan-ligand interactions in congenital muscular dystrophies. Nature 2002, 418:417-422. 10.1038/nature00837, 12140558.
57. Jimenez-Mallebrera C, Torelli S, Feng L, Kim J, Godfrey C, Clement E, Mein R, Abbs S, Brown SC, Campbell KP, Kröger S, Talim B, Topaloglu H, Quinlivan R, Roper H, Childs AM, Kinali M, Sewry CA, Muntoni F. A comparative study of alpha-dystroglycan glycosylation in dystroglycanopathies suggests that the hypoglycosylation of alpha-dystroglycan does not consistently correlate with clinical severity. Brain Pathol 2009, 19:596-611. 10.1111/j.1750-3639.2008.00198.x, 2860390, 18691338.
58. Kim DS, Hayashi YK, Matsumoto H, Ogawa M, Noguchi S, Murakami N, Sakuta R, Mochizuki M, Michele DE, Campbell KP, Nonaka I, Nishino I. POMT1 mutation results in defective glycosylation and loss of laminin-binding activity in alpha-DG. Neurology 2004, 62:1009-1011.
59. Longman C, Brockington M, Torelli S, Jimenez-Mallebrera C, Kennedy C, Khalil N, Feng L, Saran RK, Voit T, Merlini L, Sewry CA, Brown SC, Muntoni F. Mutations in the human LARGE gene cause MDC1D, a novel form of congenital muscular dystrophy with severe mental retardation and abnormal glycosylation of alpha-dystroglycan. Hum Mol Genet 2003,
60. Sewry CA, Muntoni F. Inherited disorders of the extracellular matrix. Curr Opin Neurol 1999, 12:519-526. 10.1097/00019052-199910000-00005, 10590888.
61. Macleod H, Pytel P, Wollmann R, Chelmicka-Schorr E, Silver K, Anderson RB, Waggoner D, McNally EM. A novel FKRP mutation in congenital muscular dystrophy disrupts the dystrophin glycoprotein complex. Neuromuscul Disord 2007, 17:285-289. 10.1016/j.nmd.2007.01.005, 17336067.
62. Sewry CA, Philpot J, Mahony D, Wilson LA, Muntoni F, Dubowitz V. Expression of laminin subunits in congenital muscular dystrophy. Neuromuscul Disord 1995, 5:307-316. 10.1016/0960-8966(94)00072-H, 7580244.
63. Sewry CA, Naom I, D'Alessandro M, Sorokin L, Bruno S, Wilson LA, Dubowitz V, Muntoni F. Variable clinical phenotype in merosin-deficient congenital muscular dystrophy associated with differential immunolabelling of two fragments of the laminin alpha 2 chain. Neuromuscul Disord 1997, 7:169-175. 10.1016/S0960-8966(97)00425-2, 9185180.
64. Sewry CA, D'Alessandro M, Wilson LA, Sorokin LM, Naom I, Bruno S, Ferlini A, Dubowitz V, Muntoni F. Expression of laminin chains in skin in merosin-deficient congenital muscular dystrophy. Neuropediatrics 1997, 28:217-222. 10.1055/s-2007-973703, 9309712.
65. Marbini A, Bellanova MF, Ferrari A, Lodesani M, Gemignani F. Immunohistochemical study of merosin-negative congenital muscular dystrophy: laminin alpha 2 deficiency in skin biopsy. Acta Neuropathologica 1997, 94:103-108. 10.1007/s004010050680, 9255383.
66. Naom I, Sewry C, D'Alessandro M, Topaloglu H, Ferlini A, Wilson L, Dubowitz V, Muntoni F. Prenatal diagnosis in merosin-deficient congenital muscular dystrophy. Neuromuscul Disord 1997, 7:176-179. 10.1016/S0960-8966(97)00448-3, 9185181.
67. Jimenez-Mallebrera C, Brown SC, Sewry CA, Muntoni F. Congenital muscular dystrophy: molecular and cellular aspects. Cell Mol Life Sci 2005, 62:809-823. 10.1007/s00018-004-4510-4, 15868406.
68. Muntoni F, Brockington M, Godfrey C, Ackroyd M, Robb S, Manzur A, Kinali M, Mercuri E, Kaluarachchi M, Feng L, Jimenez-Mallebrera C, Clement E, Torelli S, Sewry CA, Brown SC. Muscular dystrophies due to defective glycosylation of dystroglycan. Acta Myol 2007, 26:129-135. 2949305, 18646561.
69. Faulkner G, Lanfranchi G, Valle G. Telethonin and other new proteins of the Z-disc of skeletal muscle. IUBMB Life 2001, 51:275-282. 10.1080/152165401317190761, 11699871.
70. Hauser MA, Conde CB, Kowaljow V, Zeppa G, Taratuto AL, Torian UM, Vance J, Pericak-Vance MA, Speer MC, Rosa AL. Myotilin mutation found in second pedigree with LGMD1A. Am J Hum Genet 2002, 71:1428-1432. 10.1086/344532, 378586, 12428213.
71. Hauser MA, Horrigan SK, Salmikangas P, Torian UM, Viles KD, Dancel R, Tim RW, Taivainen A, Bartoloni L, Gilchrist JM, Stajich JM, Gaskell PC, Gilbert JR, Vance JM, Pericak-Vance MA, Carpen O, Westbrook CA, Speer MC. Myotilin is mutated in limb girdle muscular dystrophy 1A. Hum Mol Genet 2000, 9:2141-2147. 10.1093/hmg/9.14.2141, 10958653.
72. Selcen D, Engel AG. Mutations in myotilin cause myofibrillar myopathy. Neurology 2004, 62:1363-1371.
73. Foroud T, Pankratz N, Batchman AP, Pauciulo MW, Vidal R, Miravalle L, Goebel HH, Cushman LJ, Azzarelli B, Horak H, Farlow M, Nichols WC. A mutation in myotilin causes spheroid body myopathy. Neurology 2005, 65:1936-1940. 10.1212/01.wnl.0000188872.28149.9a, 16380616.
74. Penisson-Besnier I, Talvinen K, Dumez C, Vihola A, Dubas F, Fardeau M, Hackman P, Carpen O, Udd B. Myotilinopathy in a family with late onset myopathy. Neuromuscul Disord 2006, 16:427-431. 10.1016/j.nmd.2006.04.009, 16793270.
75. Selcen D, Ohno K, Engel AG. Myofibrillar myopathy: clinical, morphological and genetic studies in 63 patients. Brain 2004, 127:439-451. 10.1093/brain/awh052, 14711882.
76. Schroder R, Schoser B. Myofibrillar myopathies: a clinical and myopathological guide. Brain Pathol 2009, 19:483-492. 10.1111/j.1750-3639.2009.00289.x, 19563540.
77. Schessl J, Taratuto AL, Sewry C, Battini R, Chin SS, Maiti B, Dubrovsky AL, Erro MG, Espada G, Robertella M, Saccoliti M, Olmos P, Bridges LR, Standring P, Hu Y, Zou Y, Swoboda KJ, Scavina M, Goebel HH, Mitchell CA, Flanigan KM, Muntoni F, Bönnemann CG. Clinical, histological and genetic characterization of reducing body myopathy caused by mutations in FHL1. Brain 2009, 132:452-464. 2724920, 19181672.
78. Hübbers CU, Clemen CS, Kesper K, Böddrich A, Hofmann A, Kämäräinen O, Tolksdorf K, Stumpf M, Reichelt J, Roth U, Krause S, Watts G, Kimonis V, Wattjes MP, Reimann J, Thal DR, Biermann K, Evert BO, Lochmüller H, Wanker EE, Schoser BG, Noegel AA, Schröder R. Pathological consequences of VCP mutations on human striated muscle. Brain 2007, 130:381-393. 10.1093/brain/awl238, 16984901.
79. McNally EM, de Sá Moreira E, Duggan DJ, Bönnemann CG, Lisanti MP, Lidov HG, Vainzof M, Passos-Bueno MR, Hoffman EP, Zatz M, Kunkel LM. Caveolin-3 in muscular dystrophy. Hum Mol Genet 1998, 7:871-877. 10.1093/hmg/7.5.871, 9536092.
80. Minetti C, Sotgia F, Bruno C, Scartezzini P, Broda P, Bado M, Masetti E, Mazzocco M, Egeo A, Donati MA, Volonte D, Galbiati F, Cordone G, Bricarelli FD, Lisanti MP, Zara F. Mutations in the caveolin-3 gene cause autosomal dominant limb-girdle muscular dystrophy. Nat Genet 1998, 18:365-368. 10.1038/ng0498-365, 9537420.
81. Crosbie RH, Yamada H, Venzke DP, Lisanti MP, Campbell KP. Caveolin-3 is not an integral component of the dystrophin glycoprotein complex. FEBS Lett 1998, 427:279-282. 10.1016/S0014-5793(98)00442-6, 9607328.
82. Gazzerro E, Sotgia F, Bruno C, Lisanti MP, Minetti C. Caveolinopathies: from the biology of caveolin-3 to human diseases. Eur J Hum Genet 2010, 18:137-145. 10.1038/ejhg.2009.103, 2987183, 19584897.
83. Schoser B, Jacob S, Hilton-Jones D, Müller-Felber W, Kubisch C, Claus D, Goebel HH, Vita G, Vincent A, Toscano A, Van den Bergh P. Immune-mediated rippling muscle disease with myasthenia gravis: a report of seven patients with long-term follow-up in two. Neuromuscul Disord 2009, 19:223-228. 10.1016/j.nmd.2009.01.002, 19208478.
84. Hayashi YK, Matsuda C, Ogawa M, Goto K, Tominaga K, Mitsuhashi S, Park YE, Nonaka I, Hino-Fukuyo N, Haginoya K, Sugano H, Nishino I. Human PTRF mutations cause secondary deficiency of caveolins resulting in muscular dystrophy with generalized lipodystrophy. J Clin Invest 2009, 119:2623-2633. 10.1172/JCI38660, 2735915, 19726876.
85. Rajab A, Straub V, McCann LJ, Seelow D, Varon R, Barresi R, Schulze A, Lucke B, Lützkendorf S, Karbasiyan M, Bachmann S, Spuler S, Schuelke M. Fatal cardiac arrhythmia and long-QT syndrome in a new form of congenital generalized lipodystrophy with muscle rippling (CGL4) due to PTRF-CAVIN mutations. PLoS Genet 2010, 6:e1000874. 10.1371/journal.pgen.1000874, 2837386, 20300641.
86. Matsuda C, Hayashi YK, Ogawa M, Aoki M, Murayama K, Nishino I, Nonaka I, Arahata K, Brown RH. The sarcolemmal proteins dysferlin and caveolin-3 interact in skeletal muscle. Hum Mol Genet 2001, 10:1761-1766. 10.1093/hmg/10.17.1761, 11532985.
87. Richard I, Broux O, Allamand V, Fougerousse F, Chiannilkulchai N, Bourg N, Brenguier L, Devaud C, Pasturaud P, Roudaut C, Hillaire D, Passos-Bueno MR, Zatz M, Tischfield JA, Fardeau M, Jackson CE, Cohen D, Beckmann JS. Mutations in the proteolytic enzyme calpain 3 cause limb-girdle muscular dystrophy type 2A. Cell 1995, 81:27-40. 10.1016/0092-8674(95)90368-2, 7720071.
88. Anderson LV, Davison K, Moss JA, Richard I, Fardeau M, Tome FM, Hubner C, Lasa A, Colomer J, Beckmann JS. Characterization of monoclonal antibodies to calpain 3 and protein expression in muscle from patients with limb-girdle muscular dystrophy type 2A. Am J Pathol 1998, 153:1169-1179. 10.1016/S0002-9440(10)65661-1, 1853046, 9777948.
89. Taveau M, Bourg N, Sillon G, Roudaut C, Bartoli M, Richard I. Calpain 3 is activated through autolysis within the active site and lyses sarcomeric and sarcolemmal components. Mol Cell Biol 2003, 23:9127-9135. 10.1128/MCB.23.24.9127-9135.2003, 309685, 14645524.
90. Charlton R, Henderson M, Richards J, Hudson J, Straub V, Bushby K, Barresi R. Immunohistochemical analysis of calpain 3: advantages and limitations in diagnosing LGMD2A. Neuromuscul Disord 2009, 19:449-457. 10.1016/j.nmd.2009.05.005, 19556129.
91. Kolski HK, Hawkins C, Zatz M, de Paula F, Biggar D, Alman B, Vajsar J. Diagnosis of limb-girdle muscular dystrophy 2A by immunohistochemical techniques. Neuropathology 2008, 28:264-268. 10.1111/j.1440-1789.2007.00871.x, 18031465.
92. Anderson LV, Davison K, Moss JA, Richard I, Fardeau M, Tome FM, Hubner C, Lasa A, Colomer J, Beckmann JS. Characterization of monoclonal antibodies to calpain 3 and protein expression in muscle from patients with limb-girdle muscular dystrophy type 2A. Am J Pathol 1998, 153:1169-1179. 10.1016/S0002-9440(10)65661-1, 1853046, 9777948.
93. Vainzof M, Anderson LV, McNally EM, Davis DB, Faulkner G, Valle G, Moreira ES, Pavanello RC, Passos-Bueno MR, Zatz M. Dysferlin protein analysis in limb-girdle muscular dystrophies. J Mol Neurosci 2001, 17:71-80. 10.1385/JMN:17:1:71, 11665864.
94. A Anderson LV, Harrison RM, Pogue R, Vafiadaki E, Pollitt C, Davison K, Moss JA, Keers S, Pyle A, Shaw PJ, Mahjneh I, Argov Z, Greenberg CR, Wrogemann K, Bertorini T, Goebel HH, Beckmann JS, Bashir R, Bushby KM. Secondary reduction in calpain 3 expression in patients with limb girdle muscular dystrophy type 2B and Miyoshi myopathy (primary dysferlinopathies). Neuromuscul Disord 2000, 10:553-559. 10.1016/S0960-8966(00)00143-7, 11053681.
95. Haravuori H, Vihola A, Straub V, Auranen M, Richard I, Marchand S, Voit T, Labeit S, Somer H, Peltonen L, Beckmann JS, Udd B. Secondary calpain3 deficiency in 2q-linked muscular dystrophy: titin is the candidate gene. Neurology 2001, 56:869-877.
96. Sorimachi H, Toyama-Sorimachi N, Saido TC, Kawasaki H, Sugita H, Miyasaka M, Arahata K, Ishiura S, Suzuki K. Muscle-specific calpain, p94, is degraded by autolysis immediately after translation, resulting in disappearance from muscle. J Biol Chem 1993, 268:10593-10605.
97. Groen EJ, Charlton R, Barresi R, Anderson LV, Eagle M, Hudson J, Koref MS, Straub V, Bushby KM. Analysis of the UK diagnostic strategy for limb girdle muscular dystrophy 2A. Brain 2007, 130:3237-3249. 10.1093/brain/awm259, 18055493.
98. Fanin M, Nascimbeni AC, Fulizio L, Trevisan CP, Meznaric-Petrusa M, Angelini C. Loss of calpain-3 autocatalytic activity in LGMD2A patients with normal protein expression. Am J Pathol 2003, 163:1929-1936. 10.1016/S0002-9440(10)63551-1, 1892408, 14578192.
99. Bashir R, Britton S, Strachan T, Keers S, Vafiadaki E, Lako M, Richard I, Marchand S, Bourg N, Argov Z, Sadeh M, Mahjneh I, Marconi G, Passos-Bueno MR, Moreira Ede S, Zatz M, Beckmann JS, Bushby K. A gene related to Caenorhabditis elegans spermatogenesis factor fer-1 is mutated in limb-girdle muscular dystrophy type 2B. Nat Genet 1998, 20:37-42. 10.1038/1689, 9731527.
100. Liu J, Aoki M, Illa I, Wu C, Fardeau M, Angelini C, Serrano C, Urtizberea JA, Hentati F, Hamida MB, Bohlega S, Culper EJ, Amato AA, Bossie K, Oeltjen J, Bejaoui K, McKenna-Yasek D, Hosler BA, Schurr E, Arahata K, de Jong PJ, Brown RH. Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy. Nat Genet 1998, 20:31-36. 10.1038/1682, 9731526.
101. Illa I, Serrano-Munuera C, Gallardo E, Lasa A, Rojas-Garcia R, Palmer J, Gallano P, Baiget M, Matsuda C, Brown RH. Distal anterior compartment myopathy: a dysferlin mutation causing a new muscular dystrophy phenotype. Ann Neurol 2001, 49:130-134. 10.1002/1531-8249(200101)49:1<130::AID-ANA22>3.0.CO;2-0, 11198284.
102. Bansal D, Miyake K, Vogel SS, Groh S, Chen CC, Williamson R, McNeil PL, Campbell KP. Defective membrane repair in dysferlin-deficient muscular dystrophy. Nature 2003, 423:168-172. 10.1038/nature01573, 12736685.
103. Han R, Bansal D, Miyake K, Muniz VP, Weiss RM, McNeil PL, Campbell KP. Dysferlin-mediated membrane repair protects the heart from stress-induced left ventricular injury. J Clin Invest 2007, 117:1805-1813. 10.1172/JCI30848, 1904311, 17607357.
104. Piccolo F, Moore SA, Ford GC, Campbell KP. Intracellular accumulation and reduced sarcolemmal expression of dysferlin in limb--girdle muscular dystrophies. Ann Neurol 2000, 48:902-912. 10.1002/1531-8249(200012)48:6<902::AID-ANA11>3.0.CO;2-Z, 11117547.
105. Anderson LV, Harrison RM, Pogue R, Vafiadaki E, Pollitt C, Davison K, Moss JA, Keers S, Pyle A, Shaw PJ, Mahjneh I, Argov Z, Greenberg CR, Wrogemann K, Bertorini T, Goebel HH, Beckmann JS, Bashir R, Bushby KM. Secondary reduction in calpain 3 expression in patients with limb girdle muscular dystrophy type 2B and Miyoshi myopathy (primary dysferlinopathies). Neuromuscul Disord 2000, 10:553-559. 10.1016/S0960-8966(00)00143-7, 11053681.
106. Matsuda C, Hayashi YK, Ogawa M, Aoki M, Murayama K, Nishino I, Nonaka I, Arahata K, Brown RH. The sarcolemmal proteins dysferlin and caveolin-3 interact in skeletal muscle. Hum Mol Genet 2001, 10:1761-1766. 10.1093/hmg/10.17.1761, 11532985.
107. Lo HP, Cooper ST, Evesson FJ, Seto JT, Chiotis M, Tay V, Compton AG, Cairns AG, Corbett A, MacArthur DG, Yang N, Reardon K, North KN. Limb-girdle muscular dystrophy: diagnostic evaluation, frequency and clues to pathogenesis. Neuromuscul Disord 2008, 18:34-44. 10.1016/j.nmd.2007.08.009, 17897828.
108. Chrobakova T, Hermanova M, Kroupova I, Vondracek P, Marikova T, Mazanec R, Zamecnik J, Stanek J, Havlova M, Fajkusova L. Mutations in Czech LGMD2A patients revealed by analysis of calpain3 mRNA and their phenotypic outcome. Neuromuscul Disord 2004, 14:659-665. 10.1016/j.nmd.2004.05.005, 15351423.
109. Anderson LV, Davison K, Moss JA, Young C, Cullen MJ, Walsh J, Johnson MA, Bashir R, Britton S, Keers S, Argov Z, Mahjneh I, Fougerousse F, Beckmann JS, Bushby KM. Dysferlin is a plasma membrane protein and is expressed early in human development. Hum Mol Genet 1999, 8:855-861. 10.1093/hmg/8.5.855, 10196375.
110. De Luna N, Freixas A, Gallano P, Caselles L, Rojas-García R, Paradas C, Nogales G, Dominguez-Perles R, Gonzalez-Quereda L, Vílchez JJ, Márquez C, Bautista J, Guerrero A, Salazar JA, Pou A, Illa I, Gallardo E. Dysferlin expression in monocytes: a source of mRNA for mutation analysis. Neuromuscul Disord 2007, 17:69-76. 10.1016/j.nmd.2006.09.006, 17070050.
111. Fanin M, Nascimbeni AC, Angelini C. Muscle protein analysis in the detection of heterozygotes for recessive limb girdle muscular dystrophy type 2B and 2E. Neuromuscul Disord 2006, 16:792-799. 10.1016/j.nmd.2006.06.010, 16934466.
112. Moreira ES, Wiltshire TJ, Faulkner G, Nilforoushan A, Vainzof M, Suzuki OT, Valle G, Reeves R, Zatz M, Passos-Bueno MR, Jenne DE. Limb-girdle muscular dystrophy type 2G is caused by mutations in the gene encoding the sarcomeric protein telethonin. Nat Genet 2000, 24:163-166. 10.1038/72822, 10655062.
113. Olive M, Shatunov A, Gonzalez L, Carmona O, Moreno D, Quereda LG, Martinez-Matos JA, Goldfarb LG, Ferrer I. Transcription-terminating mutation in telethonin causing autosomal recessive muscular dystrophy type 2G in a European patient. Neuromuscul Disord 2008, 18:929-933. 10.1016/j.nmd.2008.07.009, 2592511, 18948002.
114. Vainzof M, Moreira ES, Suzuki OT, Faulkner G, Valle G, Beggs AH, Carpen O, Ribeiro AF, Zanoteli E, Gurgel-Gianneti J, Tsanaclis AM, Silva HC, Passos-Bueno MR, Zatz M. Telethonin protein expression in neuromuscular disorders. Biochim Biophys Acta 2002, 1588:33-40.
115. Bione S, Maestrini E, Rivella S, Mancini M, Regis S, Romeo G, Toniolo D. Identification of a novel X-linked gene responsible for Emery-Dreifuss muscular dystrophy. Nat Genet 1994, 8:323-327. 10.1038/ng1294-323, 7894480.
116. Yorifuji H, Tadano Y, Tsuchiya Y, Ogawa M, Goto K, Umetani A, Asaka Y, Arahata K. Emerin, deficiency of which causes Emery-Dreifuss muscular dystrophy, is localized at the inner nuclear membrane. Neurogenetics 1997, 1:135-140. 10.1007/s100480050020, 10732816.
117. Yates JR, Bagshaw J, Aksmanovic VM, Coomber E, McMahon R, Whittaker JL, Morrison PJ, Kendrick-Jones J, Ellis JA. Genotype-phenotype analysis in X-linked Emery-Dreifuss muscular dystrophy and identification of a missense mutation associated with a milder phenotype. Neuromuscul Disord 1999, 9:159-165. 10.1016/S0960-8966(98)00121-7, 10382909.
118. Manilal S, Recan D, Sewry CA, Hoeltzenbein M, Llense S, Leturcq F, Deburgrave N, Barbot J, Man N, Muntoni F, Wehnert M, Kaplan J, Morris GE. Mutations in Emery-Dreifuss muscular dystrophy and their effects on emerin protein expression. Hum Mol Genet 1998, 7:855-864. 10.1093/hmg/7.5.855, 9536090.
119. Manilal S, Sewry CA, Man N, Muntoni F, Morris GE. Diagnosis of X-linked Emery-Dreifuss muscular dystrophy by protein analysis of leucocytes and skin with monoclonal antibodies. Neuromuscul Disord 1997, 7:63-66. 10.1016/S0960-8966(96)00405-1, 9132142.
120. Sabatelli P, Squarzoni S, Petrini S, Capanni C, Ognibene A, Cartegni L, Cobianchi F, Merlini L, Toniolo D, Maraldi NM. Oral exfoliative cytology for the non-invasive diagnosis in X-linked Emery-Dreifuss muscular dystrophy patients and carriers. Neuromuscul Disord 1998, 8:67-71. 10.1016/S0960-8966(97)00147-8, 9696599.
121. Mora M, Cartegni L, Di Blasi C, Barresi R, Bione S, Raffaele di Barletta M, Morandi L, Merlini L, Nigro V, Politano L, Donati MA, Cornelio F, Cobianchi F, Toniolo D. X-linked Emery-Dreifuss muscular dystrophy can be diagnosed from skin biopsy or blood sample. Ann Neurol 1997, 42:249-253. 10.1002/ana.410420218, 9266737.
122. Worman HJ, Bonne G. "Laminopathies": a wide spectrum of human diseases. Exp Cell Res 2007, 313:2121-2133. 10.1016/j.yexcr.2007.03.028, 2964355, 17467691.
123. Raffaele Di Barletta M, Ricci E, Galluzzi G, Tonali P, Mora M, Morandi L, Romorini A, Voit T, Orstavik KH, Merlini L, Trevisan C, Biancalana V, Housmanowa-Petrusewicz I, Bione S, Ricotti R, Schwartz K, Bonne G, Toniolo D. Different mutations in the LMNA gene cause autosomal dominant and autosomal recessive Emery-Dreifuss muscular dystrophy. Am J Hum Genet 2000, 66:1407-1412. 10.1086/302869, 1288205, 10739764.
124. Zhang Q, Bethmann C, Worth NF, Davies JD, Wasner C, Feuer A, Ragnauth CD, Yi Q, Mellad JA, Warren DT, Wheeler MA, Ellis JA, Skepper JN, Vorgerd M, Schlotter-Weigel B, Weissberg PL, Roberts RG, Wehnert M, Shanahan CM. Nesprin-1 and -2 are involved in the pathogenesis of Emery Dreifuss muscular dystrophy and are critical for nuclear envelope integrity. Hum Mol Genet 2007, 16:2816-2833. 10.1093/hmg/ddm238, 17761684.
125. Gueneau L, Bertrand AT, Jais JP, Salih MA, Stojkovic T, Wehnert M, Hoeltzenbein M, Spuler S, Saitoh S, Verschueren A, Tranchant C, Beuvin M, Lacene E, Romero NB, Heath S, Zelenika D, Voit T, Eymard B, Ben Yaou R, Bonne G. Mutations of the FHL1 gene cause Emery-Dreifuss muscular dystrophy. Am J Hum Genet 2009, 85:338-353. 10.1016/j.ajhg.2009.07.015, 2771595, 19716112.
126. Camacho Vanegas O, Bertini E, Zhang RZ, Petrini S, Minosse C, Sabatelli P, Giusti B, Chu ML, Pepe G. Ullrich scleroatonic muscular dystrophy is caused by recessive mutations in collagen type VI. Proc Natl Acad Sci USA 2001, 98:7516-7521. 10.1073/pnas.121027598, 34700, 11381124.
127. Demir E, Sabatelli P, Allamand V, Ferreiro A, Moghadaszadeh B, Makrelouf M, Topaloglu H, Echenne B, Merlini L, Guicheney P. Mutations in COL6A3 cause severe and mild phenotypes of Ullrich congenital muscular dystrophy. Am J Hum Genet 2002, 70:1446-1458. 10.1086/340608, 419991, 11992252.
128. Pan TC, Zhang RZ, Sudano DG, Marie SK, Bonnemann CG, Chu ML. New molecular mechanism for Ullrich congenital muscular dystrophy: a heterozygous in-frame deletion in the COL6A1 gene causes a severe phenotype. Am J Hum Genet 2003, 73:355-369. 10.1086/377107, 1180372, 12840783.
129. Scacheri PC, Gillanders EM, Subramony SH, Vedanarayanan V, Crowe CA, Thakore N, Bingler M, Hoffman EP. Novel mutations in collagen VI genes: expansion of the Bethlem myopathy phenotype. Neurology 2002, 58:593-602.
130. Lampe AK, Bushby KM. Collagen VI related muscle disorders. J Med Genet 2005, 42:673-685. 10.1136/jmg.2002.002311, 1736127, 16141002.
131. Ishikawa H, Sugie K, Murayama K, Ito M, Minami N, Nishino I, Nonaka I. Ullrich disease: collagen VI deficiency: EM suggests a new basis for muscular weakness. Neurology 2002, 59:920-923.
132. Mercuri E, Yuva Y, Brown SC, Brockington M, Kinali M, Jungbluth H, Feng L, Sewry CA, Muntoni F. Collagen VI involvement in Ullrich syndrome: a clinical, genetic, and immunohistochemical study. Neurology 2002, 58:1354-1359.
133. Hicks D, Lampe AK, Barresi R, Charlton R, Fiorillo C, Bonnemann CG, Hudson J, Sutton R, Lochmüller H, Straub V, Bushby K. A refined diagnostic algorithm for Bethlem myopathy. Neurology 2008, 70:1192-1199. 10.1212/01.wnl.0000307749.66438.6d, 18378883.
134. Sabatelli P, Bonaldo P, Lattanzi G, Braghetta P, Bergamin N, Capanni C, Mattioli E, Columbaro M, Ognibene A, Pepe G, Bertini E, Merlini L, Maraldi NM, Squarzoni S. Collagen VI deficiency affects the organization of fibronectin in the extracellular matrix of cultured fibroblasts. Matrix Biol 2001, 20:475-486. 10.1016/S0945-053X(01)00160-3, 11691587.
135. Fanin M, Nascimbeni AC, Aurino S, Tasca E, Pegoraro E, Nigro V, Angelini C. Frequency of LGMD gene mutations in Italian patients with distinct clinical phenotypes. Neurology 2009, 72:1432-1435. 10.1212/WNL.0b013e3181a1885e, 19380703.
136. Muntoni F. Is a muscle biopsy in Duchenne dystrophy really necessary?. Neurology 2001, 57:574-575.